News & Updates
Filter by Specialty:
Vonoprazan-amoxicillin on par with quadruple therapy for H pylori eradication
Dual therapy with vonoprazan and amoxicillin (VA-dual) for 10 days results in a 90.8-percent eradication rate of Helicobacter pylori (H pylori) and fewer adverse events (AEs) compared with the standard 14-day bismuth-based quadruple therapy (B-quadruple), a study has shown.
Vonoprazan-amoxicillin on par with quadruple therapy for H pylori eradication
09 May 2024Could 15 years be the new 10 for repeat colonoscopy?
Adults who have tested negative for colorectal cancer (CRC) on initial colonoscopy and have no family history of CRC may only need to undergo a repeat screening after 15 years, according to a new Swedish study.
Could 15 years be the new 10 for repeat colonoscopy?
09 May 2024Olanzapine vs fosaprepitant: Which is better for CINV prevention?
Olanzapine appears to be just as effective as fosaprepitant, a neurokinin-1 receptor antagonist (NK1-RA), in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic malignancies who were receiving carboplatin/paclitaxel chemotherapy every 3 weeks, a prospective study presented at SGO 2024 suggests. However, the former trumps the latter in terms of cost effectiveness.
Olanzapine vs fosaprepitant: Which is better for CINV prevention?
09 May 2024More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC
Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide reported more fatigue, depression and deterioration in perceived cognitive ability, and slower reaction time than those receiving abiraterone acetate, according to results of the ACE study.